Hydroxychloroquine is an autophagy inhibitor that is currently being evaluated in a study along with MEK-inhibitor binimetinib for the treatment of patients with KRAS-mutated lung cancer (NCT04735068). The gene discussed is KRAS; the disease is lung carcinoma.